SCHEMBL5106237

SCHEMBL5106237

CCOC(=O)c1c(Cc2c(C)nn(-c3ncccn3)c2C)sc2c1c(=O)n(C)c(=O)n2C(C)C

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC16A1 P53985 9/20 0.41
PDE4D Q08499 1/20 0.34
KDM4E B2RXH2 1/20 0.34
CYP3A4 P08684 6/20 0.33
CYP2C9 P11712 6/20 0.33
SLC16A3 O15427 1/20 0.33
P2RX7 Q99572 1/20 0.33
LMNA P02545 2/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PDE4B Q07343 1/20 0.32
SLC16A7 O60669 1/20 0.32
MAPT P10636 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
ATM Q13315 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5100047 0.88 SLC16A1 (0.41) SLC16A1PDE4DKDM4ECYP3A4CYP2C9
SCHEMBL4838695 0.82 SLC16A1 (0.55) SLC16A1CYP3A4CYP2C9SLC16A3SLC16A7
SCHEMBL5106150 0.81 SLC16A1 (0.39) SLC16A1CYP3A4CYP2C9SLC16A3SLC16A7
SCHEMBL5139602 0.81 SLC16A1 (0.39) SLC16A1CYP3A4CYP2C9SLC16A3SLC16A7
SCHEMBL5100191 0.81 SLC16A1 (0.40) SLC16A1CYP3A4CYP2C9SLC16A3SLC16A7
SCHEMBL5140584 0.81 SLC16A1 (0.40) SLC16A1CYP3A4CYP2C9SLC16A3SLC16A7
SCHEMBL4833502 0.79 SLC16A1 (0.43) SLC16A1CYP3A4CYP2C9SLC16A3SLC16A7
SCHEMBL5093395 0.79 SLC16A1 (0.42) SLC16A1KDM4ECYP3A4CYP2C9SLC16A3
SCHEMBL5097159 0.78 SLC16A1 (0.46) SLC16A1KDM4ECYP3A4CYP2C9LMNA
SCHEMBL5106258 0.77 SLC16A1 (0.42) SLC16A1KDM4ECYP3A4CYP2C9SLC16A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214579-A1 THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE ASTRAZENECA AB (SE) 2008-09-04 US disclosed
US-7384951-B2 Thienopyrimidinediones and their use in the modulation of autoimmune disease ASTRAZENECA AB (SE) 2008-06-10 US disclosed
US-20060052400-A1 Thienopyriminediones and their use in the modulation of autoimmune disease ASTRAZENECA AB (SE) 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214579-A1 THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE TPMT, TYMP, TYMS SLC16A1 3968/4885PDE4D 510/4885KDM4E 1441/4885
US-20060052400-A1 Thienopyriminediones and their use in the modulation of autoimmune disease C5, HRH4, CYP2S1 SLC16A1 4250/4885PDE4D 2245/4885KDM4E 1300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.